Expand ARWR Menu
ARWR MENU

ARWR Latest Press Releases

-- April 26, 2024 --

Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars Business Wire 7:30 AM

-- April 24, 2024 --

Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results Business Wire 4:01 PM
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease Business Wire 7:30 AM

-- April 16, 2024 --

Turnstone Biologics Appoints William Waddill to its Board of Directors Globe Newswire 9:00 AM

-- April 7, 2024 --

Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo Business Wire 9:00 AM

-- April 1, 2024 --

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Business Wire 4:30 PM

-- March 25, 2024 --

Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data Business Wire 8:00 AM

-- March 8, 2024 --

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy Business Wire 7:30 AM

-- March 4, 2024 --

Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences Business Wire 7:30 AM

-- February 6, 2024 --

Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results Business Wire 4:01 PM

-- January 22, 2024 --

Arrowhead Pharmaceuticals to Webcast Fiscal 2024 First Quarter Results Business Wire 4:01 PM

-- January 5, 2024 --

Arrowhead Pharmaceuticals Closes Underwritten Offering with Gross Proceeds of $450.0 Million Business Wire 5:00 PM

-- January 3, 2024 --

Arrowhead Pharmaceuticals Announces Pricing of $450.0 Million Underwritten Offering of Common Stock Business Wire 7:00 AM

-- December 29, 2023 --

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Business Wire 4:01 PM

-- December 21, 2023 --

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB for Complement Mediated Kidney Disease Business Wire 7:30 AM

-- December 20, 2023 --

Arrowhead Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference Business Wire 7:30 AM

-- November 29, 2023 --

Arrowhead Pharmaceuticals Reports Fiscal 2023 Year End Results Business Wire 4:01 PM

-- November 28, 2023 --

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy Business Wire 7:30 AM